Hahn v. Oregon Physicians Service

689 F.2d 840, 1982 U.S. App. LEXIS 25049
CourtCourt of Appeals for the Ninth Circuit
DecidedOctober 5, 1982
DocketNo. 81-3173
StatusPublished
Cited by22 cases

This text of 689 F.2d 840 (Hahn v. Oregon Physicians Service) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hahn v. Oregon Physicians Service, 689 F.2d 840, 1982 U.S. App. LEXIS 25049 (9th Cir. 1982).

Opinion

FARRIS, Circuit Judge:

Plaintiff-podiatrists filed four separate actions in September 1978 alleging that the defendants conspired or combined to boycott podiatrists in favor of other physicians in violation of the Clayton Act, 15 U.S.C. § 12 et seq., and the Sherman Act, 15 U.S.C. § 1 et seq. After initial discovery the defendants moved for summary judgment and the district court granted the motion on February 27,1981. Hahn v. Oregon Physicians’ Service, 508 F.Supp. 970 (D.Or.1981). We reverse and remand for further proceedings.

I. FACTS

Plaintiffs are doctors of podiatric medicine licensed to practice in Oregon. Or.Rev. Stat. § 682.020. Defendants are providers of prepaid health insurance. The defendants include state regulated health care contractors, Or.Rev.Stat. § 750.005(2)(a); federally regulated health maintenance organizations, 42 U.S.C. § 300e; and a federally regulated individual practice association, 42 U.S.C. § 300e-l(5). The plaintiffs challenge three of the defendants’ practices: (1) insureds are required to obtain certain podiatric services exclusively from medical doctors; (2) insureds are not reimbursed for treatment by a podiatrist unless they are referred by an M.D.; and (3) podiatrists are not allowed to be members of defendant health-care associations. The effect of the latter practice is that podiatrists are reimbursed for their services at a lower rate than are members of the defendant organizations.

The district court granted the defendants’ summary judgment motion, finding that the McCarran-Ferguson Act, 15 U.S.C. § 1011 et seq., exempts defendants from antitrust liability and that the plaintiffs failed to meet the interstate commerce jurisdictional requirement of the Sherman Act.

II. DISCUSSION

A. McCarran-Ferguson Act

The threshold issue is whether the district court was correct in finding the challenged activities of the defendant health-care providers exempt from antitrust laws under the McCarran-Ferguson Act, 15 U.S.C. § 1012(b). We reverse this ruling. ' The exemption is inapplicable upon the facts in issue.

1) Introduction

The primary purpose of the McCarran-Ferguson Act is to allow for state regulation of the activities of insurance companies. 15 U.S.C. § 1011 et seq. A secondary purpose is to give insurance companies limited immunity from antitrust laws. See Group Life & Health Ins. Co. v. Royal Drug Co., 440 U.S. 205, 218 & n.18, 99 S.Ct. 1067, 1077 & n.18, 59 L.Ed.2d 261 (1979). To qualify for an exemption from the federal antitrust laws, the anticompeti[842]*842tive practices 1) must be part of the “business of insurance,” 2) must be regulated by state law, and 3) may not take the form of coercion, intimidation, or boycott. See 15 U.S.C. §§ 1012(b) and 1013(b). The pivotal question is whether the defendants’ activities were part of the “business of insurance.”

2) Precedent

The Supreme Court limited the scope of the antitrust exemption in Group Life & Health Ins. Co. v. Royal Drug Co., 440 U.S. 205, 99 S.Ct. 1067, 59 L.Ed.2d 261 (1979), by narrowly defining the statutory term “business of insurance.” The Court recently reaffirmed this holding. Union Labor Life Insur. Co. v. Pireno, -U.S. -,-, -, 102 S.Ct. 3002, 3006-08, 73 L.Ed.2d 647 (1982). In Royal Drug independent pharmacists filed an antitrust action against Blue Shield, a health insurer, and several participating pharmacies challenging provider-agreements. The defendants contended that the provider contracts were not subject to the federal antitrust laws because the provider contracts constituted the “business of insurance” and were therefore exempt under the McCarran-Ferguson Act. The Supreme Court disagreed and in its ruling adopted a narrow interpretation of the statutory language, the “business of insurance.”

In holding that the pharmacy agreements were not the “business of insurance” within the meaning of § 2(b), the Court based its ruling in part on the common understanding of that term. Royal Drug, 440 U.S. at 211, 99 S.Ct. at 1073. The Court identified three relevant criteria for determining if a business practice is part of the “business of insurance:” “first, whether the practice has the effect of transferring or spreading a policyholder’s risk; second, whether the practice is an integral part of the policy relationship between the insurer and the insured; and third, whether the practice is limited to entities within the insurance industry.” Union Labor Life Insurance Co. v. Pireno, - U.S. -,-, 102 S.Ct. 3002, 3008, 73 L.Ed.2d 647 (1982). See also Royal Drug, 410 U.S. at 211—12, 215, 231, 99 S.Ct. at 1073, 1075, 1083.

The insurance contract involves a contractual relationship which exists when an insurer, for consideration, agrees to reimburse an insured for loss caused by designated contingencies. See Black’s Law Dictionary 721 (5th Ed. 1979). This underwriting and subsequent spreading of the policyholder’s risk is the primary element of the insurance contract and is, therefore, the “business of insurance.” Royal Drug, 440 U.S. at 211, 99 S.Ct. at 1073. The Court in Royal Drug recognized that the provider contracts neither served to spread the risk nor to define the peril, but were merely a cost-cutting device for the insurers. Id. at 214-15, 99 S.Ct. at 1074-75. The provider contracts established an “arrangement for the purchase of goods and services” that reduced the insurer’s cost of covering the loss that it was obligated to cover under the insurance contract. Id. at 214, 99 S.Ct. at 1074.1 The Court concluded that this primary element of risk-spreading was missing in the provider agreements.

The Court in Royal Drug also found that the provider agreement was not an “integral part of the contract between the insurer and the insured,” 440 U.S. at 215-16, 99 S.Ct. at 1075, and that it involved entities outside the insurance industry. Id. at 224, 231, 99 S.Ct. at 1080, 1083. See Pireno, - U.S. at -, 102 S.Ct. at 3008.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Washington Physicians Service Ass'n v. Gregoire
967 F. Supp. 424 (W.D. Washington, 1997)
Litman v. A. Barton Hepburn Hospital
679 F. Supp. 196 (N.D. New York, 1988)
Bhan v. NME Hospitals, Inc.
669 F. Supp. 998 (E.D. California, 1987)
Reazin v. Blue Cross & Blue Shield of Kansas, Inc.
663 F. Supp. 1360 (D. Kansas, 1987)
INSURANCE BD. UNDER SOCIAL INS. PLAN v. Muir
635 F. Supp. 1425 (M.D. Pennsylvania, 1986)
Wright v. Southern Mono Hospital District
631 F. Supp. 1294 (E.D. California, 1986)
State of Md. v. Blue Cross and Blue Shield
620 F. Supp. 907 (D. Maryland, 1985)
Aron v. Michigan Health Care Corp.
600 F. Supp. 483 (D. Nevada, 1984)
Hayden v. Bracy
744 F.2d 1338 (Eighth Circuit, 1984)
Addino v. Genesee Valley Medical Care, Inc.
593 F. Supp. 892 (W.D. New York, 1984)

Cite This Page — Counsel Stack

Bluebook (online)
689 F.2d 840, 1982 U.S. App. LEXIS 25049, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hahn-v-oregon-physicians-service-ca9-1982.